Protocol Ledger

NCT06424288 · Phase III · RECRUITING

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

Interventional Phase III clinical trial protocol NCT06424288 sponsored by Boehringer Ingelheim in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-06-17 Enrollment: 6,712 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06424288
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)6,712 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06424288
Protocol FieldVerified Registry Value
NCT IdentifierNCT06424288
Consolidated Lead SponsorBoehringer Ingelheim
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment6,712 participants (ESTIMATED)
Registered Start Date2024-06-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06424288
Hospital Research SiteLocationSite Profile
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Boehringer Ingelheim across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI